More U.S. adults believe it is a good thing than a bad thing for adults to use weight-loss drugs like Ozempic, Wegovy and ...
A new poll from The Associated Press-NORC Center for Public Affairs Research shows about half of U.S. adults believe it is a ...
Cost is a major obstacle for many. The drugs can be expensive without insurance, with out-of-pocket expenses reaching ...
The top 20 biopharmaceutical companies experienced mixed performance in 2024 amid a dynamic landscape influenced by various ...
As founder of Coatue Management, Philippe Laffont oversees $26.9 billion invested in more than 80 stocks, and though he buys ...
We came across a bullish thesis on Novo Nordisk A/S (NVO) on Long-Term Pick’s Substack by Dan. In this article, we will summarize the bulls’ thesis on NVO.
Weight loss drugs are popular—but often expensive. Luckily, there are a few ways to lower the costs, which we explore in this article.
Its weight-loss drug policy would fall to Trump's pick for health secretary, Robert F Kennedy Jr, and Mehmet Oz, Trump's choice to lead Medicare and Medicaid services. But this could mean a potential ...
Kennedy is nominated to lead the Department of Health and Human Services, a position that would give him enormous control ...
Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...
A Medscape survey found that a strong majority of physicians believe high-risk patients should have easier access to new weight loss drugs.
A woman who lost 64 pounds on a compounded form of the weight loss drug semaglutide, marketed as Wegovy and Ozempic, started ...